Several analysts have recently updated their ratings and price targets for Aflac (NYSE: AFL):

  • 7/12/2017 – Aflac had its “sell” rating reaffirmed by analysts at Royal Bank Of Canada. They now have a $66.00 price target on the stock.
  • 7/12/2017 – Aflac had its “market perform” rating reaffirmed by analysts at FBR & Co. They now have a $80.00 price target on the stock, up previously from $68.00.
  • 7/7/2017 – Aflac was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aflac’s shares have gained 11.4% outperforming the Zacks categorized Accident and Health Insurance industry's increase of 10.4% year to date. The company's efforts to increase agent productivity, emphasis on sale of third-sector products, pull back on sale of first-sector products, introduction of new product like cancer insurance are likely to drive long-term growth. Its strong capital position enables it to buy back shares and increase dividend payouts. However, it remains exposed to a challenging operating environment, primarily in Japan. Moreover, its U.S. business has been facing stiff competition in the middle market, which in turn, has been denting its sales. In 2016 and the first quarter of 2017, the company recorded disappointing U.S. sales figures.”
  • 7/4/2017 – Aflac was upgraded by analysts at Bank of America Corporation from an “underperform” rating to a “neutral” rating. They now have a $78.00 price target on the stock, up previously from $75.00.
  • 7/3/2017 – Aflac had its price target raised by analysts at Barclays PLC from $71.00 to $73.00. They now have an “equal weight” rating on the stock.
  • 6/6/2017 – Aflac was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aflac’s shares have gained 9.1% outperforming the Zacks categorized Accident and Health Insurance industry's increase of 6% year to date. The company's efforts to increase agent productivity, emphasis on sale of third-sector products, pull back on sale of first-sector products, introduction of new product like cancer insurance are likely to drive long-term growth. Its strong capital position enables it to buy back shares and increase dividend payouts. However, it remains exposed to a challenging operating environment, primarily in Japan. Moreover, its U.S. business has been facing stiff competition in the middle market, which in turn, has been denting its sales. In 2016 and the first quarter of 2017, the company recorded disappointing U.S. sales figures.”
  • 6/2/2017 – Aflac was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $84.00 price target on the stock. According to Zacks, “Aflac’s shares have gained 9.1% outperforming the Zacks categorized Accident and Health Insurance industry's increase of 6% year to date. The company's efforts to increase agent productivity, emphasis on sale of third-sector products, pull back on sale of first-sector products, introduction of new product like cancer insurance are likely to drive long-term growth. Its strong capital position enables it to buy back shares and increase dividend payouts. However, it remains exposed to a challenging operating environment, primarily in Japan. Moreover, its U.S. business has been facing stiff competition in the middle market, which in turn, has been denting its sales. In 2016 and the first quarter of 2017, the company recorded disappointing U.S. sales figures.”
  • 5/31/2017 – Aflac was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Aflac’s efforts to increase agent productivity, emphasis on sale of third-sector products, pull back on sale of first-sector products, introduction of new product like cancer insurance are likely to drive long-term growth. Its strong capital position enables it to buy back shares and increase dividend payouts. However, it remains exposed to a challenging operating environment, primarily in Japan. Moreover, its U.S. business has been facing stiff competition in the middle market, which in turn, has been denting its sales. In 2016, the company recorded disappointing U.S. sales figures. The shares have underperformed the Zacks categorized Accident and Health Insurance industry year to date.”

Shares of Aflac Incorporated (AFL) opened at 77.75 on Tuesday. Aflac Incorporated has a 52 week low of $66.50 and a 52 week high of $79.86. The company has a market capitalization of $30.85 billion, a PE ratio of 12.65 and a beta of 0.99. The firm’s 50-day moving average price is $76.01 and its 200 day moving average price is $72.67.

Aflac (NYSE:AFL) last released its quarterly earnings data on Thursday, April 27th. The financial services provider reported $1.67 EPS for the quarter, beating the Zacks’ consensus estimate of $1.62 by $0.05. The company had revenue of $5.31 billion during the quarter, compared to the consensus estimate of $5.40 billion. Aflac had a net margin of 11.24% and a return on equity of 12.82%. Aflac’s quarterly revenue was down 2.6% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.74 EPS. Equities analysts predict that Aflac Incorporated will post $6.52 EPS for the current year.

In other Aflac news, insider Teresa L. White sold 11,314 shares of the stock in a transaction dated Tuesday, June 27th. The shares were sold at an average price of $78.01, for a total value of $882,605.14. Following the completion of the sale, the insider now owns 26,847 shares in the company, valued at approximately $2,094,334.47. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Paul S. Amos II sold 222,889 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $77.40, for a total transaction of $17,251,608.60. Following the completion of the sale, the insider now owns 329,540 shares of the company’s stock, valued at approximately $25,506,396. The disclosure for this sale can be found here. In the last quarter, insiders sold 236,703 shares of company stock valued at $18,328,514. 3.00% of the stock is owned by insiders.

Aflac Incorporated is a business holding company. The Company is involved in supplemental health and life insurance, which is marketed and administered through its subsidiary, American Family Life Assurance Company of Columbus (Aflac). The Company’s insurance business consists of two segments: Aflac Japan and Aflac U.S.

Receive News & Ratings for Aflac Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aflac Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.